The global market for chronic kidney disease (CKD) drugs is experiencing significant growth, projected to reach $23.8 billion by 2034, fueled by rising CKD prevalence, advancements in treatment, and the emergence of new drug classes like SGLT2 inhibitors. North America currently holds the largest market share, driven by a high incidence of CKD in the US.